- Advertisement -

Loss of critical enzymatic processes can increase bone fracture risk

A loss of enzymatic processes within the body can increase a person's risk of bone fracture. This new insight was recently published in eLife...

Kicking Up an Immune System Storm: COVID-19 and Hyper-Inflammation

/* custom css */ .td_uid_1_5ed5bb3a69f36_rand { min-height: 0; } /* custom css */ .td_uid_2_5ed5bb3a6a187_rand { vertical-align: baseline; } REGISTER NOW jQuery(window).load(function () { jQuery('body').find('#td_uid_1_5ed5bb3a69f30 .td-element-style').each(function...

PET imaging validates use of common cholesterol drug to enhance HER2-targeted cancer therapy

Reston, VA—A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number...

Plant receptors that control immunity and development share a common origin

Plants are continuously evolving new immune receptors to ever-changing pathogens. Researchers at the RIKEN Center for Sustainable Resource Science (CSRS) have traced the origin...

UNM Researchers Uncover Mechanism of Toxic Metal Nanoparticles from MRI Scans...

University of New Mexico researchers have recently unveiled alarming new findings regarding gadolinium, a rare earth metal commonly used as a contrast agent in...

Solutions for Improved Work-Life Balance of High-Throughput Bioprocess Development

Broadcast Date: July 29, 2021Time: 8:00 am PT, 11:00 am ET, 17:00 CET REGISTER NOW We often hear that work-life balance is an essential...

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors...

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans...

Elix and University of Vienna Aim to Advance Drug Discovery Using...

Tokyo-based Elix and the University of Vienna signed a joint research agreement aimed at advancing drug discovery using AI technologies. One of Elix’s business models...

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans...

Elix and University of Vienna Aim to Advance Drug Discovery Using AI

Tokyo-based Elix and the University of Vienna signed a joint research agreement aimed at advancing drug discovery using AI technologies. One of Elix’s business models...

Base Editing Strategy Alleviates Huntington’s Disease in Mice

According to at least one estimate, approximately 41,000 people in the United States have symptoms of Huntington’s disease, and more than 200,000 are at-risk...

more new items

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors...

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans...

Elix and University of Vienna Aim to Advance Drug Discovery Using...

Tokyo-based Elix and the University of Vienna signed a joint research agreement aimed at advancing drug discovery using AI technologies. One of Elix’s business models...

Base Editing Strategy Alleviates Huntington’s Disease in Mice

According to at least one estimate, approximately 41,000 people in the United States have symptoms of Huntington’s disease, and more than 200,000 are at-risk...